How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Treatment of MSRA infections

Organization name

PROvendis GmbH



Infection with methicillin-resistant Staphylococcus aureus (MRSA) is a major health problem in hospitals, long-term care facilities, and community medicine settings worldwide. There are new compounds in development for the treatment of MRSA. Unfortunately, there is a significant risk that new antibiotics targeting pathogen-specific proteins will exert the sort of selective pressure on the pathogen that ultimately leads to antibiotic resistance. Consequently, there is still a medical need for new antibiotics targeting MRSA.

The inventors of the present invention identified derivatives of the bis-indol-compounds hyrtinadine A and allocasine A as being active against MRSA. The minimum inhibitory concentration of compounds is in the sub-micromolar range. The strong bactericidal effect seems to suppress the formation of any resistances.

Next to its potency, easy synthetical access is a key feature of the compounds of the present invention. The compounds are accessible by a one-pot synthesis. The molecular scaffold may easily be modified in order to develop further derivatives.

Commercial Opportunities

On behalf of University of Düsseldorf, PROvendis offers the invention for licensing.

Competitive Advantages

  • High potency
  • Ease of synthetical access

Current Status                                                                                                       

A European priority application has been filed.

Relevant Publication

Tasch, B.O. et al. (2013) Masuda borylation-Suzuki coupling (MBSC) sequence of vinylhalides and its application in a one-pot synthesis of 3,4-biarylpyrazoles. Org.Biomol. Chem. 11(36): 6113-8

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries